The global animal model market size was valued at USD 2.91 billion in 2025 and is projected to grow from USD 3.15 billion in 2026 to USD 5.99 billion by 2034, registering a CAGR of 8.36% during the forecast period from 2026 to 2034. North America dominated the animal model market with a market share of 41.8% in 2025.
Animal models are living animals used in biomedical research to study biological processes, diseases, drug efficacy, safety, and potential therapeutic approaches. Common models include mice, rats, rabbits, zebrafish, and other laboratory animals selected according to research requirements. Animal models help researchers understand disease mechanisms, evaluate experimental treatments, assess drug toxicity, and generate preclinical data before potential therapies advance to human clinical studies.
Download a Free Sample To learn more about this report,
Growing Development of Humanized Immune-System Models
The animal model market is increasingly moving toward humanized models containing functional human immune components rather than relying entirely on conventional laboratory animals. These models can provide more clinically relevant information about immune responses, tumor biology, and therapeutic mechanisms because selected elements of human immunity are recreated within the animal. This makes them particularly valuable for immuno-oncology and antibody development. Humanized research platforms are therefore becoming an important part of animal model market trends.
In June 2026, Charles River Laboratories expanded its humanized mouse portfolio with next-generation immune-oncology models supporting engraftment of human immune cells and evaluation of multiple therapeutic modalities within the same preclinical research platform.
Increasing Adoption of Aged Animal Models for Longevity Research
Biomedical research is increasingly using naturally aged animals to investigate diseases whose biology changes substantially with age. Older models can reproduce age-associated changes in metabolism, immunity, cognition, and tissue function that young laboratory animals cannot fully represent. Growing research into Alzheimer's disease, frailty, cardiovascular disorders, and healthy longevity is therefore creating specialized demand for animals across defined age groups. Age-specific modeling is consequently expanding the animal model industry into longevity and geroscience applications.
In October 2025, The Jackson Laboratory expanded its aged-mouse program with C57BL/6J animals available at ages reaching approximately 130 weeks, supporting studies of aging, age-associated disease, and interventions intended to extend healthy lifespan.
Expansion of Oncology Drug Pipelines Increases Preclinical Model Requirements
Cancer therapies require extensive preclinical evaluation before human studies because developers need evidence on tumor response, pharmacology, toxicity, and treatment combinations. Patient-derived xenografts and other tumor models allow researchers to evaluate therapies against biologically diverse cancers rather than relying exclusively on simplified cell cultures. A larger oncology pipeline therefore creates recurring requirements for specialized in vivo research systems. Continued cancer-drug development is strengthening animal model market demand.
In April 2025, Crown Bioscience expanded its oncology model collection beyond 3,000 patient-derived xenograft and cell-derived xenograft models, providing researchers with tumor systems covering more than 30 cancer indications.
Regulatory Shift Toward Non-Animal Testing Can Reduce Model Utilization
Regulators and pharmaceutical developers are increasingly exploring organoids, computational models, organ-on-chip systems, and other new approach methodologies to replace animal testing where scientifically appropriate. As these technologies become validated, some toxicity and drug-development studies may require fewer animals or eliminate specific animal experiments entirely. This structural change can reduce demand for conventional models in selected applications. Expansion of alternative testing methods can consequently restrain animal model market growth.
In April 2025, the FDA announced a plan to reduce animal testing requirements for monoclonal antibodies and other drugs by encouraging AI-based computational models, organoids, and organ-on-chip approaches, beginning with a roadmap intended to make animal studies the exception rather than the default for selected programs.
Expansion of Genetically Engineered Models for Rare Diseases
Rare genetic disorders provide a distinct opportunity because researchers need models containing specific human disease mutations to investigate disease mechanisms and evaluate gene, RNA, and precision therapies. CRISPR-based engineering can create these mutations more quickly than traditional breeding approaches, enabling highly customized research models for relatively small patient populations. Suppliers with strong genome-engineering capabilities can therefore serve specialized preclinical programs that conventional models cannot address. Rare-disease research can help providers increase animal model market share.
In February 2026, Taconic Biosciences expanded its custom genetically engineered model services using CRISPR-based approaches capable of producing knockout, knock-in, point-mutation, and humanized rodent models for specialized disease-research programs.
Maintaining Microbiome Consistency Across Research Colonies
The gut microbiome can influence immunity, metabolism, inflammation, neurological function, and therapeutic response, meaning animals with identical genetics may still produce different experimental outcomes when their microbial communities differ. Transportation, housing, diet, breeding practices, and facility conditions can all alter microbiome composition. Research providers must therefore control and characterize microbial status to improve reproducibility between experiments and laboratories. Microbiome variability remains a major challenge as animal model market size expands into increasingly precise biomedical research.
In September 2026, Inotiv expanded microbiome characterization and health-monitoring capabilities across its laboratory animal operations, applying molecular screening panels covering more than 50 microbial agents to strengthen colony-quality and reproducibility controls.
Mice Segment Dominated the Market with 48.7% Share in 2025
The mice segment dominated the global animal model market with a 48.7% share in 2025, driven by their genetic similarity to humans, well-established research protocols, relatively short reproductive cycles, and suitability for developing disease models. Mice are extensively used in biomedical research, preclinical studies, genetics, immunology, oncology, and drug development, supporting their widespread adoption across research institutions and pharmaceutical organizations.
The rat segment continues to play an important role in pharmacology, toxicology, neuroscience, and behavioral research because of its physiological characteristics and established use in laboratory studies. The guinea pig segment is supported by applications in immunology, infectious disease research, respiratory studies, and vaccine development.
The rabbit segment is gaining demand in areas such as antibody production, ophthalmology, cardiovascular research, and medical device evaluation. Other animal models contribute to market growth through specialized applications where alternative species are required for specific physiological, genetic, or disease-related research needs.
Request Customizationto receive a tailored report.
Drug Discovery and Development Segment Dominated the Market with 55.9% Share in 2025
The drug discovery and development segment dominated the global animal model market with a 55.9% share in 2025, driven by the extensive use of animal models for evaluating drug efficacy, safety, pharmacokinetics, and potential toxicity before clinical trials. Increasing pharmaceutical R&D activities and the development of therapies for complex diseases continue to support demand for reliable preclinical animal models.
The basic research segment is expanding through increasing use of animal models in genetics, physiology, neuroscience, immunology, and disease-mechanism studies. Researchers rely on established animal models to understand biological processes and investigate potential therapeutic targets. Other applications contribute to market demand through specialized research, educational activities, and testing requirements across biomedical and life science fields.
Pharma and Biotech Companies Segment Dominated the Market with 58.6% Share in 2025
The pharma and biotech companies segment dominated the global animal model market with a 58.6% share in 2025, supported by extensive preclinical research activities required for drug discovery, development, safety assessment, and therapeutic validation. Increasing investment in novel medicines and biologic therapies is encouraging pharmaceutical and biotechnology companies to utilize animal models throughout the development process.
The academic research institutes segment is expanding through increasing biomedical research, disease investigation, genetics studies, and translational research activities. Academic institutions use animal models to investigate fundamental biological mechanisms and evaluate potential therapeutic approaches. Other end-users contribute to demand through contract research, specialized testing, government-supported research, and other life science activities.
Speak to an Analystto discuss market opportunities.
The North American animal model market accounted for 41.8% of the global market, reaching USD 1.22 billion in 2025. The region holds the largest market share, supported by extensive biomedical research activities, established pharmaceutical and biotechnology industries, strong research infrastructure, and continued demand for preclinical testing and disease-model development.
The United States represents a major market in North America. Its large pharmaceutical and biotechnology sector, extensive academic research infrastructure, and strong focus on drug discovery and preclinical research continue to support demand for animal models.
Canada's established biomedical research ecosystem, pharmaceutical industry, and academic research institutions continue to support the development and use of animal models in preclinical studies.
Unlock Regional Insightsto access country-level data, & regional trends.
The European animal model market accounted for 28.6% of the global market, reaching USD 0.83 billion in 2025, and is projected to grow at the fastest CAGR of 9.3% during the forecast period. Growth is supported by increasing pharmaceutical research, biotechnology development, preclinical testing, and investments in advanced disease and genetic models.
Germany represents a major European market. Its strong pharmaceutical and biotechnology industries, research institutions, and expanding preclinical research activities continue to support animal model adoption.
The United Kingdom's established life sciences sector, academic research base, and pharmaceutical research activities continue to drive demand for animal models in biomedical and preclinical research.
The Asia Pacific animal model market accounted for 21.4% of the global market, reaching USD 0.62 billion in 2025, and is expected to grow at a CAGR of 8.9% during the forecast period. Expanding pharmaceutical and biotechnology industries, increasing research investments, and growing preclinical drug development activities continue to support regional market growth.
China represents a major market within the Asia Pacific. Its expanding pharmaceutical and biotechnology sectors, increasing biomedical research investments, and growing drug discovery activities continue to support animal model market development.
Japan's advanced pharmaceutical industry, established biomedical research infrastructure, and strong focus on life sciences research continue to support demand for animal models.
India's expanding pharmaceutical and biotechnology industries, increasing research and development activities, and growing preclinical testing requirements continue to create opportunities for animal model market growth.
Latin America's animal model market accounted for 4.7% of the global market, reaching USD 0.14 billion in 2025, and is projected to grow at a CAGR of 7.5% during the forecast period. Expansion of pharmaceutical research, biotechnology activities, and biomedical research infrastructure continues to support regional demand.
Brazil represents a major regional market. Its growing pharmaceutical sector, biomedical research capabilities, and expanding academic research activities continue to support animal model adoption.
The Middle East & Africa animal model market accounted for 3.5% of the global market, reaching USD 0.10 billion in 2025, and is anticipated to grow at a CAGR of 7.1% during the forecast period. Increasing healthcare and life sciences investments, research infrastructure development, and growing pharmaceutical activities continue to support regional market expansion.
The UAE's investments in healthcare, biotechnology, and scientific research infrastructure continue to create opportunities for animal model market development.
Saudi Arabia's expanding healthcare and life sciences ecosystem, research investments, and pharmaceutical development activities continue to support demand for animal models in biomedical research.
The global animal model market is highly competitive, with leading contract research organizations, biotechnology companies, laboratory animal suppliers, and preclinical research providers competing through genetically engineered models, transgenic animals, knockout models, humanized models, disease-specific models, and customized research services. The major players in the market include Charles River Laboratories, The Jackson Laboratory, Genoway S.A., Taconic Biosciences, Inc., Janvier Labs, Harbour BioMed, Crown Bioscience, Envigo RMS, LLC, Inotiv, BIOCYTOGEN, BioSpherix, Ltd., Ozgene Pty, Trans Genic Inc., Hera BioLabs, and B&K Universal, among others.
Industry participants are focusing on developing more predictive and disease-relevant animal models to support drug discovery, toxicology, immunology, oncology, and preclinical research. Companies are investing in genetically engineered models, humanized immune-system models, precision breeding, CRISPR-based gene editing, cryopreservation, model characterization, and customized research services. Growing pharmaceutical and biotechnology R&D expenditure, increasing drug development activity, demand for translational research models, and rising adoption of genetically modified and humanized animals are encouraging companies to expand their model portfolios and research capabilities.
Charles River Laboratories is one of the leading companies in the global animal model market, providing laboratory animal models, genetically engineered models, preclinical research services, and specialized discovery and development solutions for pharmaceutical and biotechnology companies. Its portfolio supports research across oncology, immunology, infectious diseases, metabolic disorders, and other therapeutic areas.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Europe Tangential Flow Filtration Market Size, Share & Trends | Industry Report, 2034
Asia Pacific Genetic Testing Market Size, 2034
North America TB Diagnostics Market Size & Trends Analysis, 2034
U.S Direct to Consumer Laboratory Testing Market Size, Share and Forecast to 2034
Non-invasive Prenatal Testing Market Size, Share, Growth, 2034
Vaccines Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com